Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025)

Immatics (IMTX) posted Total Non-Current Liabilities of $41.0 million for Q4 2025, down 11.47% sequentially from $46.3 million in Q3 2025, and down 28.03% YoY from $57.0 million in Q4 2024.

Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends

Immatics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $41.0 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 28.03% year-over-year to $41.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41.0 million (down 28.03% YoY) and the FY2025 annual result came in at $39.8 million, down 31.03% from the prior year.
  • Total Non-Current Liabilities fell to $41.0 million in Q4 2025 per IMTX's latest filing, from $46.3 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $146.1 million in Q4 2023 and troughed at $41.0 million in Q4 2025.
  • A 5-year average of $83.3 million and a median of $78.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities surged 76.84% in 2022, then plunged 61.01% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $63.4 million in 2021, then surged by 57.69% to $100.0 million in 2022, then surged by 46.11% to $146.1 million in 2023, then plunged by 61.01% to $57.0 million in 2024, then declined by 28.03% to $41.0 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $41.0 million, $46.3 million, and $51.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Immatics 1.27 Bn 719.31 Mn - 41.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 41.00 Mn
Sep 30, 2025 46.32 Mn
Jun 30, 2025 51.48 Mn
Mar 31, 2025 51.87 Mn
Dec 31, 2024 56.97 Mn
Sep 30, 2024 75.95 Mn
Jun 30, 2024 103.55 Mn
Mar 31, 2024 119.38 Mn
Dec 31, 2023 146.11 Mn
Sep 30, 2023 74.62 Mn
Jun 30, 2023 73.69 Mn
Mar 31, 2023 83.53 Mn
Dec 31, 2022 100.00 Mn
Sep 30, 2022 118.10 Mn
Jun 30, 2022 138.04 Mn
Mar 31, 2022 83.44 Mn
Dec 31, 2021 63.42 Mn
Sep 30, 2021 66.78 Mn
Jun 30, 2021 80.61 Mn
Mar 31, 2021 91.77 Mn